[go: up one dir, main page]

MX2021010700A - Compuestos utiles en la terapia del vih. - Google Patents

Compuestos utiles en la terapia del vih.

Info

Publication number
MX2021010700A
MX2021010700A MX2021010700A MX2021010700A MX2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A
Authority
MX
Mexico
Prior art keywords
compounds useful
hiv therapy
hiv
compounds
therapy
Prior art date
Application number
MX2021010700A
Other languages
English (en)
Inventor
John F Miller
B Narasimhulu Naidu
Emile Johann Velthuisen
David Temelkoff
La Rosa Martha Alicia De
Vicente Samano
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2021010700A publication Critical patent/MX2021010700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula (I), sales de los mismos, composiciones farmacéuticas de los mismos, así como a métodos para tratar o prevenir el VIH en sujetos.
MX2021010700A 2019-03-06 2020-03-04 Compuestos utiles en la terapia del vih. MX2021010700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
MX2021010700A true MX2021010700A (es) 2021-10-01

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010700A MX2021010700A (es) 2019-03-06 2020-03-04 Compuestos utiles en la terapia del vih.

Country Status (22)

Country Link
US (3) US12240853B2 (es)
EP (1) EP3934760A1 (es)
JP (1) JP2022525013A (es)
KR (1) KR20210136052A (es)
CN (1) CN113811360A (es)
AR (1) AR118240A1 (es)
AU (1) AU2020231934B2 (es)
BR (1) BR112021017604A2 (es)
CA (1) CA3132112A1 (es)
CL (1) CL2021002309A1 (es)
CO (1) CO2021012579A2 (es)
CR (1) CR20210460A (es)
EA (1) EA202192433A1 (es)
IL (1) IL285894A (es)
MA (1) MA55200A (es)
MX (1) MX2021010700A (es)
PE (1) PE20212089A1 (es)
PH (1) PH12021500034A1 (es)
SG (1) SG11202109253SA (es)
TW (1) TW202102233A (es)
WO (1) WO2020178767A1 (es)
ZA (1) ZA202106096B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003369A4 (en) * 2019-07-27 2023-10-18 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
EP4072520A1 (en) * 2019-12-09 2022-10-19 VIIV Healthcare Company Pharmaceutical compositions comprising cabotegravir
AR121620A1 (es) * 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
JP2024503723A (ja) * 2021-01-25 2024-01-26 ブリー バイオサイエンシーズ， インコーポレイテッド アデノシン誘導体及びそれを含む医薬組成物
CA3204255A1 (en) 2021-01-25 2022-07-28 Lianhong Xu Combination therapy for hiv with adenosine derivative and capsid inhibitors
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物
TW202434594A (zh) * 2023-01-30 2024-09-01 美商默沙東有限責任公司 ４＇－經取代之核苷反轉錄酶抑制劑之前藥
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1177201B1 (en) 1999-05-12 2003-09-24 Yamasa Corporation 4'-c-ethynyl pyrimidine nucleosides
JPWO2002074769A1 (ja) 2001-03-19 2004-07-08 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体を有効成分として含有する薬剤
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
TW201321508A (zh) 2011-10-06 2013-06-01 Dow Agrosciences Llc 靶定ｒｐａ７０且賦予對鞘翅目害蟲抗性之核酸分子
CA3107640A1 (en) 2011-12-22 2013-06-27 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PL2827875T3 (pl) 2012-03-21 2019-07-31 Janssen Biopharma, Inc. Podstawione nukleozydy, nukleotydy i ich analogi
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AP2016009653A0 (en) 2014-06-24 2016-12-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20170313735A1 (en) * 2014-10-31 2017-11-02 Sandoz Ag Improved Fluorination Process
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP6768796B2 (ja) * 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ４’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2017223280A2 (en) 2016-06-23 2017-12-28 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
CN110325542A (zh) 2016-11-03 2019-10-11 劳伦斯·I·吴 克罗拉滨的前体药物
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
EP3774759A2 (en) 2018-04-09 2021-02-17 Eisai R&D Management Co., Ltd. Pladienolide compounds and their use
AR115936A1 (es) 2018-08-09 2021-03-17 Glaxosmithkline Ip No 2 Ltd Compuestos útiles en terapia del vih
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
JP7565293B2 (ja) 2019-03-06 2024-10-10 グリーンテック・グローバル・プライベート・リミテッド ハロゲン化アシルのための液体分散体

Also Published As

Publication number Publication date
US20240182473A1 (en) 2024-06-06
CR20210460A (es) 2022-02-03
PE20212089A1 (es) 2021-11-04
EA202192433A1 (ru) 2021-12-28
CA3132112A1 (en) 2020-09-10
AR118240A1 (es) 2021-09-22
AU2020231934A8 (en) 2022-03-24
US20220411425A1 (en) 2022-12-29
MA55200A (fr) 2022-01-12
SG11202109253SA (en) 2021-09-29
AU2020231934B2 (en) 2023-04-20
EP3934760A1 (en) 2022-01-12
TW202102233A (zh) 2021-01-16
WO2020178767A1 (en) 2020-09-10
US12240853B2 (en) 2025-03-04
JP2022525013A (ja) 2022-05-11
BR112021017604A2 (pt) 2021-11-16
AU2020231934A1 (en) 2021-09-23
IL285894A (en) 2021-10-31
PH12021500034A1 (en) 2022-06-06
US20230174534A1 (en) 2023-06-08
KR20210136052A (ko) 2021-11-16
ZA202106096B (en) 2023-03-29
CL2021002309A1 (es) 2022-09-20
CO2021012579A2 (es) 2021-10-20
CN113811360A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
PH12021500034A1 (en) Compounds useful in hiv therapy
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
MX2021001612A (es) Compuestos utiles en terapia del vih.
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
TR201819805T4 (tr) Flavaglin türevleri̇.
WO2018039077A8 (en) Therapeutic compounds
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
PH12020551620A1 (en) Compositions for preventing or treating dry eye